Suppr超能文献

乳腺癌患者首次诊断后 10-32 年内的复发情况。

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis.

机构信息

Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.

Danish Cancer Society Research Center, Copenhagen, Denmark.

出版信息

J Natl Cancer Inst. 2022 Mar 8;114(3):391-399. doi: 10.1093/jnci/djab202.

Abstract

BACKGROUND

Extended, more effective breast cancer treatments have increased the prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence (BCR), 10 years or more after primary diagnosis, and associations between patient and tumor characteristics at primary diagnosis and late BCR up to 32 years after primary breast cancer diagnosis.

METHODS

Using the Danish Breast Cancer Group clinical database, we identified all women with an incident early breast cancer diagnosed during 1987-2004. We restricted to women who survived 10 years without a recurrence or second cancer (10-year disease-free survivors) and followed them from 10 years after breast cancer diagnosis date until late recurrence, death, emigration, second cancer, or December 31, 2018. We calculated incidence rates per 1000 person-years and cumulative incidences for late BCR, stratifying by patient and tumor characteristics. Using Cox regression, we calculated adjusted hazard ratios for late BCR accounting for competing risks.

RESULTS

Among 36 924 women with breast cancer, 20 315 became 10-year disease-free survivors. Of these, 2595 developed late BCR (incidence rate = 15.53 per 1000 person-years, 95% confidence interval = 14.94 to 16.14; cumulative incidence = 16.6%, 95% confidence interval = 15.8% to 17.5%) from year 10 to 32 after primary diagnosis. Tumor size larger than 20 mm, lymph node-positive disease, and estrogen receptor-positive tumors were associated with increased cumulative incidences and hazards for late BCR.

CONCLUSIONS

Recurrences continued to occur up to 32 years after primary diagnosis. Women with high lymph node burden, large tumor size, and estrogen receptor-positive tumors had increased risk of late recurrence. Such patients may warrant extended surveillance, more aggressive treatment, or new therapy approaches.

摘要

背景

延长、更有效的乳腺癌治疗方法增加了长期生存者的比例。我们研究了原发性诊断后 10 年或更长时间的晚期乳腺癌复发(BCR)的风险,以及原发性乳腺癌诊断后 32 年内患者和肿瘤特征与晚期 BCR之间的关联。

方法

使用丹麦乳腺癌组临床数据库,我们确定了所有在 1987-2004 年期间诊断出的早期乳腺癌患者。我们将研究对象限制为在无复发或第二癌症(10 年无病幸存者)后生存 10 年的患者,并从乳腺癌诊断日期后 10 年开始对他们进行随访,直到晚期复发、死亡、移民、第二癌症或 2018 年 12 月 31 日。我们按患者和肿瘤特征对晚期 BCR 的发生率(每 1000 人年的发生率)和累积发生率进行了计算。使用 Cox 回归,我们计算了晚期 BCR 的调整后的危险比,同时考虑了竞争风险。

结果

在 36924 名乳腺癌患者中,有 20315 名成为 10 年无病幸存者。其中,2595 名患者发生晚期 BCR(发生率为 15.53/1000 人年,95%置信区间为 14.94 至 16.14;累积发生率为 16.6%,95%置信区间为 15.8%至 17.5%),从原发性诊断后 10 年到 32 年。肿瘤直径大于 20mm、淋巴结阳性疾病和雌激素受体阳性肿瘤与晚期 BCR 的累积发生率和风险增加相关。

结论

在原发性诊断后 32 年内仍有复发发生。淋巴结负担高、肿瘤直径大、雌激素受体阳性的患者晚期复发风险增加。这些患者可能需要延长监测、更积极的治疗或新的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/220f/8902439/8eba8b447714/djab202f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验